Shares of Harrow, Inc. (NASDAQ:HROW – Get Free Report) have received an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $66.20.
A number of brokerages have recently weighed in on HROW. Weiss Ratings upgraded shares of Harrow from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, November 13th. Wall Street Zen upgraded shares of Harrow from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. BTIG Research reiterated a “buy” rating and issued a $63.00 target price on shares of Harrow in a research note on Wednesday, November 11th. Zacks Research downgraded shares of Harrow from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 3rd. Finally, Leerink Partners assumed coverage on shares of Harrow in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 target price on the stock.
Get Our Latest Report on Harrow
Institutional Investors Weigh In On Harrow
Harrow Stock Up 8.9%
Shares of Harrow stock opened at $32.16 on Thursday. The stock has a market capitalization of $1.21 billion, a P/E ratio of -41.23 and a beta of 0.18. The company has a quick ratio of 2.12, a current ratio of 2.29 and a debt-to-equity ratio of 10.15. The stock has a 50 day moving average price of $30.31 and a two-hundred day moving average price of $37.35. Harrow has a 12-month low of $25.76 and a 12-month high of $54.85.
Harrow (NASDAQ:HROW – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.19 by $0.06. Harrow had a negative return on equity of 69.81% and a negative net margin of 9.39%. The company had revenue of $99.30 million for the quarter, compared to the consensus estimate of $98.59 million. Equities analysts expect that Harrow will post -0.50 earnings per share for the current year.
Harrow Company Profile
Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.
Featured Stories
- Five stocks we like better than Harrow
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.
